AJANTPHARM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 59/100 — Quality 95 · Valuation 8 · Growth 47 · Momentum 79
| Share price | ₹3,469.00 |
| Market cap | ₹37,423 Cr |
| P/E ratio | 36.9 |
| P/B ratio | 8.7 |
| ROCE | 29.4% |
| Dividend yield | 1.87% |
| Book value | ₹345.45 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹5,453 Cr | ₹1,056 Cr | 28.0% |
| 2025 | ₹4,648 Cr | ₹920 Cr | 27.0% |
| 2024 | ₹4,209 Cr | ₹816 Cr | 28.0% |
| 2023 | ₹3,743 Cr | ₹588 Cr | 22.0% |
| 2022 | ₹3,341 Cr | ₹713 Cr | 28.0% |
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 19